More Articles

Generics utilization policies necessary to sustain Medicaid Generics/Research | Posted 27/03/2015

A review of the history and expansion of generics utilization policies and their critical role in the US Medicaid system in an era of reduced budgets concluded that such policies are a necessary co...

Paying physicians to prescribe generics and biosimilars in the US Biosimilars/Research | Posted 27/03/2015

Healthcare spending on prescription medications comprises 1.6% of gross domestic product (GDP) in the US and continues to rise. Brand-name prescription medications – both small-molecule and biologi...

US court rejects Amgen’s bid to block filgrastim biosimilar Biosimilars/News | Posted 27/03/2015

On 19 March 2015, the US District Court for North California rejected US biotechnology giant Amgen’s request for a preliminary injunction blocking Sandoz, the generics division of Novartis, from la...

EMA issues finalized insulin biosimilars guideline Guidelines | Posted 27/03/2015

In March 2015, the European Medicines Agency (EMA) released its finalized guideline on the non-clinical and clinical development of insulin biosimilars.

Drug manufacturers call for revision to FDA safety labelling rule Policies & Legislation | Posted 27/03/2015

Two national agencies representing manufacturers and distributors of generics and biopharmaceuticals in the US are calling on the US Food and Drug Administration (FDA) to re-write its proposed rule...

Rheumatologists want to evaluate long-term safety of biosimilars Biosimilars/General | Posted 27/03/2015

One of the biggest challenges for biosimilar companies is to convince physicians to use biosimilars instead of their well-known biological counterparts. One of the issues that physicians see as a c...

US biosimilars approvals expected to increase despite challenges Reports | Posted 27/03/2015

Biosimilar approvals in the US are expected to increase during the next five years, despite safety and regulatory challenges, according to a study from the Boston-based Tufts Center for the Study o...

Actavis loses Atelvia patents Generics/News | Posted 27/03/2015

Teva Pharmaceutical Industries (Teva) has won a legal battle against Actavis after a federal judge invalidated two patents protecting the post-menopausal osteoporosis drug Atelvia (risedronate sodi...